Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 23:13:883747.
doi: 10.3389/fimmu.2022.883747. eCollection 2022.

Lactobacillus: Friend or Foe for Systemic Lupus Erythematosus?

Weijie Wang  1 , Yongsheng Fan  2 , Xinchang Wang  1
Affiliations
Review

Lactobacillus: Friend or Foe for Systemic Lupus Erythematosus?

Weijie Wang et al. Front Immunol. .

Abstract

The cause of Systemic Lupus Erythematosus (SLE) remains largely unknown, despite the fact that it is well understood that a complex interaction between genes and environment is required for disease development. Microbiota serve as activators and are essential to immune homeostasis. Lactobacillus is thought to be an environmental agent affecting the development of SLE. However, beneficial therapeutic and anti-inflammatory effects of Lactobacillus on SLE were also explored. The discovery of Lactobacillus involvement in SLE will shed light on how SLE develops, as well as finding microbiota-targeted biomarkers and novel therapies. In this review, we attempt to describe the two sides of Lactobacillus in the occurrence, development, treatment and prognosis of SLE. We also discuss the effect of different strains Lactobacillus on immune cells, murine lupus, and patients. Finally, we try to illustrate the potential immunological mechanisms of Lactobacillus on SLE and provide evidence for further microbiota-targeted therapies.

Keywords: Lactobacillus; immunoregulators; microbiota; pathogenesis; systemic lupus erythematosus (SLE).

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Potential beneficial functions of Lactobacillus and Lactobacillus-derived bioactive metabolites in the treatment of SLE and the communication pathways on Lactobacilli-kidney axis. HDACs, histone deacetylases; GPCRs, ligands for G-protein-coupled receptors; SCFAs, Short-chain fatty acids.
Figure 2
Figure 2
Potential mechanisms by which the Lactobacillus triggers the autoimmunity of SLE.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mu Q, Zhang H, Luo XM. SLE: Another Autoimmune Disorder Influenced by Microbes and Diet? Front Immunol (2015) 6:608. doi: 10.3389/fimmu.2015.00608 - DOI - PMC - PubMed
    1. Ingvarsson RF, Bengtsson AA, Jönsen A. Variations in the Epidemiology of Systemic Lupus Erythematosus in Southern Sweden. Lupus (2016) 25:772–80. doi: 10.1177/0961203316635288 - DOI - PubMed
    1. Tsioni V, Andreoli L, Meini A, Frassi M, Raffetti E, Airò P, et al. . The Prevalence and Incidence of Systemic Lupus Erythematosus in Children and Adults: A Population-Based Study in a Mountain Community in Northern Italy. Clin Exp Rheumatol (2015) 33:681–7. - PubMed
    1. Li R, Sun J, Ren LM, Wang HY, Liu WH, Zhang XW, et al. . Epidemiology of Eight Common Rheumatic Diseases in China: A Large-Scale Cross-Sectional Survey in Beijing. Rheumatol (Oxford England) (2012) 51:721–9. doi: 10.1093/rheumatology/ker370 - DOI - PubMed
    1. Durcan L, O'Dwyer T, Petri M. Management Strategies and Future Directions for Systemic Lupus Erythematosus in Adults. Lancet (London England) (2019) 393:2332–43. doi: 10.1016/S0140-6736(19)30237-5 - DOI - PubMed

Publication types